DCTHDelcath SystemsDCTH info
$9.05info-3.52%24h
Global rank17362
Market cap$199.52M
Change 7d-
YTD Performance118.07%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Delcath Systems (DCTH) Stock Overview

    Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

    DCTH Stock Information

    Symbol
    DCTH
    Address
    1633 BroadwayNew York, NY 10019United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.delcath.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    212 489 2100

    Delcath Systems (DCTH) Price Chart

    -
    Value:-

    Delcath Systems Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $9.05
    N/A
    Market Cap
    $199.52M
    N/A
    Shares Outstanding
    22.05M
    N/A
    Employees
    52.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org